secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2026-08-05T11:08:16+00:00
Accession:  0001193125-26-333827
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam reports Q2 net loss of $64.1M; CHMP recommends EU approval for obicetrapib
--------------------------------------------------------------------------------

- CHMP positive opinion for obicetrapib monotherapy and FDC with ezetimibe; EC decision expected later 2026.
- Cash, cash equivalents and marketable securities $678.3M at June 30, 2026, down from $728.9M at Dec 31, 2025.
- Net loss $64.1M in Q2 2026 vs $17.4M in Q2 2025; revenue $3.7M vs $19.1M (prior year included $16.1M Menarini milestone).
- PREVAIL CVOT interim analysis planned for 4Q2026, result in 1Q2027; RUBENS Phase 3 topline data expected by year-end 2026.
- R&D expenses $41.7M (up from $27.5M) driven by clinical trial progression; SG&A $26.9M (down from $27.3M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/0001193125-26-333827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-333827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer